Quantitative mapping of tumor vascularity using volumetric contrast-enhanced ultrasound.
Quantitative mapping of tumor vascularity using volumetric contrast-enhanced ultrasound.
复制标题
DOI：
10.1097/rli.0b013e318234e6bc
复制
发表时间：
2012-03
影响因子：
6.7
通讯作者：
Saini R
中科院分区：
文献类型：
--
作者：
Hoyt K;Sorace A;Saini R
该研究项目的目标是开发一种体积策略，用于使用微泡造影剂和超声（US）成像实时监测和表征肿瘤血流。在配备宽带4DL 14 -5/38探头的SONIX RP US系统（Ultrasonix Medical Corp，里士满，BC）上进行容积对比增强US（VCEUS）成像。使用微泡敏感谐波成像模式（换能器以5 MHz发射并以10 MHz接收），以1 Hz的体积速率采集扫描后转换的VCEUS数据。在微泡输注后，使用定制数据处理软件来导出微泡时间-强度曲线特异性参数，即血容量（IPK）、通过时间（T1/2 PK）、流速（SPK）和肿瘤灌注（AUC）。使用临床前乳腺癌动物模型，它表明，毫米级的偏差在换能器定位可以有深远的影响，基于美国的血流估计误差范围从6.4到40.3%，并依赖于两个程度的错位（偏移）和特定的血流估计。这些错误表明，在肿瘤分析中应考虑VCEUS成像，因为它们包含整个肿块，而不仅仅是代表性的平面横截面。抗血管生成治疗药物（贝伐珠单抗）给药后，与对照肿瘤相比，肿瘤生长显著延迟（p > 0.03），反映了观察到的基于VCEUS的血流测量变化。免疫组织学数据分析显示，肿瘤内坏死水平无差异（p = 0.70），但对照组与治疗组肿瘤的MVD计数相比存在显著差异（p = 0.05）。VCEUS成像被证明是监测肿瘤血流变化的一种有前途的方式。初步的实验结果是令人鼓舞的，这种成像方式可能证明临床上可行的检测和监测早期抗肿瘤药物治疗的反应。
The goal of this research project was to develop a volumetric strategy for real-time monitoring and characterization of tumor blood flow using microbubble contrast agents and ultrasound (US) imaging. Volumetric contrast-enhanced US (VCEUS) imaging was implemented on a SONIX RP US system (Ultrasonix Medical Corp, Richmond, BC) equipped with a broadband 4DL14-5/38 probe. Using a microbubble sensitive harmonic imaging mode (transducer transmits at 5 MHz and receives at 10 MHz) acquisition of post scan-converted VCEUS data was achieved at a volume rate of 1 Hz. Following microbubble infusion, custom data processing software was used to derive microbubble time-intensity curve-specific parameters, namely, blood volume (IPK), transit time (T1/2PK), flow rate (SPK), and tumor perfusion (AUC). Using a preclinical breast cancer animal model, it is shown that millimeter-sized deviations in transducer positioning can have profound implications on US-based blood flow estimators with errors ranging from 6.4 to 40.3% and dependent on both degree of misalignment (offset) and particular blood flow estimator. These errors indicate that VCEUS imaging should be considered in tumor analyses because they incorporate the entire mass and not just a representative planar cross-section. Following administration of an antiangiogenic therapeutic drug (bevacizumab), tumor growth was significantly retarded compared to control tumors (p > 0.03) and reflect observed changes in VCEUS-based blood flow measurements. Analysis of immunohistologic data revealed no differences in intratumoral necrosis levels (p = 0.70) but a significant difference was found when comparing MVD counts in control to therapy group tumors (p = 0.05). VCEUS imaging was shown to be a promising modality for monitoring changes in tumor blood flow. Preliminary experimental results are encouraging and this imaging modality may prove clinically feasible for detecting and monitoring the early antitumor effects in response to cancer drug therapy.